AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1765336 — intervention group
Group type: EXPERIMENTAL
Intervention: Working sample using a method combining multiple regression analysis, morphological measurements, and logarithmic data transformation.
Number of subjects: 317
Study 1765336 — intervention group
Group type: COMPARATOR
Intervention: Control sample tested with the derived formulae.
Number of subjects: 317
Study 6416805 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% nitroglycerin ointment (2 cm/m2 body surface)
Number of subjects: 16
Study 6416805 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg atenolol
Number of subjects: 16
Study 6416805 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 2% nitroglycerin ointment and 50 mg atenolol
Number of subjects: 16
Study 6416805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31738179 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiarization with nine predefined app quality principles
Number of subjects: 441
Study 31738179 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent reassessment with 25 key questions
Number of subjects: 441
Study 30986326 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotary NiTi to size 20, .04 taper with syringe and needle (SNI)
Number of subjects: 96
Study 30986326 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotary NiTi to size 20, .04 taper with ultrasonically activated irrigation (UAI)
Number of subjects: 96
Study 30986326 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotary NiTi to size 40, .04 taper with syringe and needle (SNI)
Number of subjects: 96
Study 30986326 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotary NiTi to size 40, .04 taper with ultrasonically activated irrigation (UAI)
Number of subjects: 96
Study 30986326 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated canals)
Number of subjects: 96
Study 27714530 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger (500 mg) twice daily for 5 days starting on the first day of the second AC cycle
Number of subjects: 34
Study 27714530 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice daily for 5 days starting on the first day of the second AC cycle
Number of subjects: 34
Study 26045831 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 μg/kg intravenous injection for 20 min)
Number of subjects: 50
Study 26045831 — intervention group
Group type: COMPARATOR
Intervention: Control (no dexmedetomidine)
Number of subjects: 50
Study 23555741 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of IIV
Number of subjects: 26
Study 23555741 — intervention group
Group type: EXPERIMENTAL
Intervention: LAIV then IIV
Number of subjects: 26
Study 23555741 — intervention group
Group type: EXPERIMENTAL
Intervention: IIV then LAIV
Number of subjects: 26
Study 23555741 — intervention group
Group type: EXPERIMENTAL
Intervention: LAIV-IIV administration
Number of subjects: 26
Study 23555741 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 26
Study 23555741 — intervention group
Group type: COMPARATOR
Intervention: Homologous and heterologous prime boost immunization
Number of subjects: 26
Study 23555741 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterologous prime-boost vaccination
Number of subjects: 26
Study 21651947 — intervention group
Group type: EXPERIMENTAL
Intervention: SII HibP(RO) vaccine manufactured at industrial scale
Number of subjects: 204
Study 21651947 — intervention group
Group type: COMPARATOR
Intervention: SII HibP(RO) vaccine manufactured at small scale
Number of subjects: 204
Study 19384770 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrectomy with cautious removal of vitreous cortex in group A
Number of subjects: 22
Study 19384770 — intervention group
Group type: COMPARATOR
Intervention: Vitrectomy without removal of vitreous cortex in groups B and C
Number of subjects: 22
Study 16707631 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom foot orthoses
Number of subjects: 154
Study 16707631 — intervention group
Group type: COMPARATOR
Intervention: Simple sham insoles
Number of subjects: 154
Study 15560804 — intervention group
Group type: EXPERIMENTAL
Intervention: Miswak chewing stick
Number of subjects: 15
Study 15560804 — intervention group
Group type: COMPARATOR
Intervention: Toothbrush
Number of subjects: 15
Study 11213940 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide infusion at 10 microg/kg/min for 24 to 120 hours after a bolus of 0.6 mg/kg
Number of subjects: 32
Study 11213940 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide infusion
Number of subjects: 32
Study 9105824 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasmapheresis (PRP), performed before incision
Number of subjects: 40
Study 9105824 — intervention group
Group type: COMPARATOR
Intervention: Control group, managed without pheresis
Number of subjects: 40
Study 7713200 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 13
Study 7713200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 2967665 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucopolysaccharide polysulphate (MPS) cream applied twice daily
Number of subjects: 33
Study 2967665 — intervention group
Group type: COMPARATOR
Intervention: Cream base (control) applied twice daily
Number of subjects: 33
Study 28974520 — intervention group
Group type: EXPERIMENTAL
Intervention: torcetrapib plus atorvastatin
Number of subjects: 249
Study 28974520 — intervention group
Group type: COMPARATOR
Intervention: atorvastatin only
Number of subjects: 249
Study 27780197 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 200 mg/kg buccal 40% dextrose gel
Number of subjects: 416
Study 27780197 — intervention group
Group type: EXPERIMENTAL
Intervention: Any dose of dextrose gel
Number of subjects: 416
Study 27780197 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose gel
Number of subjects: 416
Study 27780197 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 416
Study 24332674 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine
Number of subjects: 712
Study 24332674 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 712
Study 23991577 — intervention group
Group type: EXPERIMENTAL
Intervention: Gow-Gates technique of inferior alveolar nerve block
Number of subjects: 32
Study 23991577 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique of inferior alveolar nerve block
Number of subjects: 32
Study 21926374 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuraxial anesthesia
Number of subjects: 70
Study 21926374 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 70
Study 18585493 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 0
Study 17150115 — intervention group
Group type: EXPERIMENTAL
Intervention: Free breakfast served at the beginning of each school day for 4 months
Number of subjects: 0
Study 17150115 — intervention group
Group type: COMPARATOR
Intervention: Control group (no breakfast served)
Number of subjects: 0
Study 12931275 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (0.3 U/kg 125I‐insulin glargine)
Number of subjects: 14
Study 12931275 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin (0.3 U/kg 125I‐NPH insulin)
Number of subjects: 14
Study 10959779 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered toothbrush prototype (B)
Number of subjects: 62
Study 10959779 — intervention group
Group type: COMPARATOR
Intervention: Marketed powered toothbrush (A)
Number of subjects: 62
Study 8617707 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50 to 200 mg daily for 10 days)
Number of subjects: 14
Study 8617707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 8617707 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (200 mg once daily for 2 days, then every 12 hours)
Number of subjects: 14
Study 8617707 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine plus Sertraline
Number of subjects: 14
Study 8617707 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine plus Placebo
Number of subjects: 14
Study 1451644 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 136
Study 1451644 — intervention group
Group type: COMPARATOR
Intervention: Pefloxacin
Number of subjects: 136
Study 44553 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% tiodonium chloride rinse
Number of subjects: 55
Study 44553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 31571176 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraventricular alteplase injections (n=251)
Number of subjects: 5686
Study 31571176 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo) injections (n=249)
Number of subjects: 5686
Study 30824955 — intervention group
Group type: EXPERIMENTAL
Intervention: Doripenem (1.0 g every 8 h)
Number of subjects: 133
Study 30824955 — intervention group
Group type: COMPARATOR
Intervention: Meropenem (1.0 g every 8 h)
Number of subjects: 133
Study 27667533 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Number of subjects: 162
Study 27667533 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine HCl (control)
Number of subjects: 162
Study 26039902 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular Contact
Number of subjects: 490
Study 26039902 — intervention group
Group type: EXPERIMENTAL
Intervention: Optional Contact
Number of subjects: 490
Study 26039902 — intervention group
Group type: EXPERIMENTAL
Intervention: No Contact
Number of subjects: 490
Study 26039902 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control Group
Number of subjects: 490
Study 23639302 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0
Study 23639302 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy participants)
Number of subjects: 0
Study 23639302 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional expressions (angry expression)
Number of subjects: 0
Study 23639302 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual and real human heads
Number of subjects: 0
Study 21324135 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose olanzapine LAI (150 mg/2 weeks)
Number of subjects: 599
Study 21324135 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium dose olanzapine LAI (405 mg/4 weeks)
Number of subjects: 599
Study 21324135 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose olanzapine LAI (300 mg/2 weeks)
Number of subjects: 599
Study 21324135 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose olanzapine LAI
Number of subjects: 599
Study 21324135 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium dose olanzapine LAI
Number of subjects: 599
Study 21324135 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose olanzapine LAI
Number of subjects: 599
Study 21324135 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of olanzapine LAI
Number of subjects: 599
Study 18852332 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose (28 g)
Number of subjects: 10
Study 18852332 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 10
Study 16764344 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA)
Number of subjects: 232
Study 16311764 — intervention group
Group type: EXPERIMENTAL
Intervention: .VO(2max) at 300 m
Number of subjects: 8
Study 16311764 — intervention group
Group type: EXPERIMENTAL
Intervention: .VO(2max) at 2,800 m
Number of subjects: 8
Study 16311764 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance time to exhaustion at constant velocity
Number of subjects: 8
Study 16311764 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial haemoglobin oxygen saturation (SpO2) at test cessation
Number of subjects: 8
Study 12791116 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion (500 micro g.kg-1 i.v. ketamine preincision and a ketamine infusion at 4 micro g.kg-1 min-1 postoperatively)
Number of subjects: 75
Study 12791116 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine bolus (500 micro g.kg-1 i.v. ketamine preincision and a saline infusion postoperatively)
Number of subjects: 75
Study 12791116 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline infusion postoperatively)
Number of subjects: 75
Study 10434830 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoretically applied lidocaine
Number of subjects: 2
Study 10434830 — intervention group
Group type: COMPARATOR
Intervention: Sham (control) group
Number of subjects: 2
Study 7672970 — intervention group
Group type: EXPERIMENTAL
Intervention: Passy-Muir Speaking Valve (PMV)
Number of subjects: 11
Study 7672970 — intervention group
Group type: COMPARATOR
Intervention: Open (unvalved) tube
Number of subjects: 11
Study 2212460 — intervention group
Group type: EXPERIMENTAL
Intervention: Near retinoscopy technique
Number of subjects: 20
Study 2212460 — intervention group
Group type: COMPARATOR
Intervention: Cycloplegic refraction
Number of subjects: 20
Study 7241426 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Number of subjects: 0
Study 7241426 — intervention group
Group type: COMPARATOR
Intervention: Atropine
Number of subjects: 0
Study 29785836 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial support intervention
Number of subjects: 173
Study 29354965 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 29354965 — intervention group
Group type: COMPARATOR
Intervention: Control acupuncture
Number of subjects: 0
Study 26604719 — intervention group
Group type: EXPERIMENTAL
Intervention: DANCE (virtual reality video game dancing)
Number of subjects: 89
Study 26604719 — intervention group
Group type: EXPERIMENTAL
Intervention: MEMORY (treadmill walking with simultaneous verbal memory training)
Number of subjects: 89
Study 26604719 — intervention group
Group type: COMPARATOR
Intervention: PHYS (treadmill walking)
Number of subjects: 89
Study 26604719 — intervention group
Group type: EXPERIMENTAL
Intervention: Global effects (all groups)
Number of subjects: 89
Study 23569309 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy with paclitaxel/gemcitabine (PG)
Number of subjects: 231
Study 23569309 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 231
Study 21165924 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic dissection
Number of subjects: 201
Study 21165924 — intervention group
Group type: COMPARATOR
Intervention: Conventional dissection
Number of subjects: 201
Study 18201644 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-held computer (PDA) intervention with monitoring and feedback
Number of subjects: 37
Study 18201644 — intervention group
Group type: COMPARATOR
Intervention: Standard information control arm (age-appropriate written physical activity educational materials)
Number of subjects: 37
Study 15975756 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Disease Self-Management Program (CDSMP)
Number of subjects: 57
Study 12512035 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine treatment for 1 year
Number of subjects: 63
Study 12512035 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine treatment for 2 additional years
Number of subjects: 63
Study 12512035 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine treatment for 3 years
Number of subjects: 63
Study 12512035 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without YMDD variants
Number of subjects: 63
Study 12512035 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with YMDD variants
Number of subjects: 63
Study 12512035 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with YMDD variants for >2 years
Number of subjects: 63
Study 12512035 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridging fibrosis improvement
Number of subjects: 63
Study 12512035 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhosis improvement
Number of subjects: 63
Study 12512035 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression to cirrhosis
Number of subjects: 63
Study 12512035 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression to bridging fibrosis
Number of subjects: 63
Study 10488603 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurolinguistic Programming (NLP) intervention applied to the experimental group (EG) consisting of 23 children; 15 sessions of NLP.
Number of subjects: 45
Study 10488603 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) with 22 children with no intervention.
Number of subjects: 45
Study 8899084 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg once daily
Number of subjects: 604
Study 8899084 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg once daily
Number of subjects: 604
Study 1904989 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin therapy at a dose of 400 mg per kilogram every three weeks
Number of subjects: 0
Study 1904989 — intervention group
Group type: COMPARATOR
Intervention: No immune globulin therapy (Control)
Number of subjects: 0
Study 7046774 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol monotherapy (329 mg daily for 12 weeks)
Number of subjects: 178
Study 7046774 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol combined with diuretics (374 mg daily for 12 weeks)
Number of subjects: 178
Study 7046774 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol monotherapy (260 mg daily for 6 months or longer)
Number of subjects: 178
Study 7046774 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol combined with diuretics (450 mg daily for 6 months or longer)
Number of subjects: 178
Study 7046774 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol for phaeochromocytoma
Number of subjects: 178
Study 31280536 — intervention group
Group type: EXPERIMENTAL
Intervention: PiCCO monitoring rehydration group
Number of subjects: 65
Study 31280536 — intervention group
Group type: COMPARATOR
Intervention: Routine rehydration group
Number of subjects: 65
Study 28013069 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week internet-based multifaceted cognitive bias modification training (CBM)
Number of subjects: 240
Study 28013069 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week school-based cognitive behavioral group training (CBT)
Number of subjects: 240
Study 28013069 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control condition
Number of subjects: 240
Study 26255456 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg i.v. dissolved in 10 ml 0.9% NaCl
Number of subjects: 72
Study 26255456 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl 10 mg)
Number of subjects: 72
Study 24310521 — intervention group
Group type: EXPERIMENTAL
Intervention: Visible collaterals
Number of subjects: 5412
Study 24310521 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients undergoing PCI with visible collaterals
Number of subjects: 5412
Study 21692846 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 30
Study 21692846 — intervention group
Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 30
Study 19650984 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine transdermal patch
Number of subjects: 119
Study 19650984 — intervention group
Group type: COMPARATOR
Intervention: Oral haloperidol
Number of subjects: 119
Study 17727931 — intervention group
Group type: EXPERIMENTAL
Intervention: Total mesometrial resection (TMMR) without adjuvant radiation
Number of subjects: 163
Study 15291907 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral desensitization with increasing doses of cow's milk starting from 0.06 mg of CM proteins
Number of subjects: 21
Study 11292409 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir implant plus oral ganciclovir (1 gm three times daily)
Number of subjects: 61
Study 11292409 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cidofovir (5 mg/kg once weekly for two doses, followed by 5 mg/kg every other week)
Number of subjects: 61
Study 11292409 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir implant plus oral ganciclovir
Number of subjects: 61
Study 11292409 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cidofovir
Number of subjects: 61
Study 9030876 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha (rhIFN-alpha2b; 5 x 10(6) U/m2)
Number of subjects: 8
Study 8292845 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 IU/day salmon calcitonin intramuscularly for 2 weeks starting on admission
Number of subjects: 40
Study 8292845 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 40
Study 3103479 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 100
Study 3103479 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 100
Study 3103479 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane and Halothane
Number of subjects: 100
Study 30762450 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of prostate atrophy (P.A.) in baseline prostate biopsies
Number of subjects: 136
Study 30762450 — intervention group
Group type: COMPARATOR
Intervention: Absence of prostate atrophy (P.A.) in baseline prostate biopsies
Number of subjects: 136
Study 28107143 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 5 mg/kg daily for 4 weeks
Number of subjects: 58
Study 28107143 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 58
Study 24520943 — intervention group
Group type: EXPERIMENTAL
Intervention: High-spatial-resolution (HR, 0.23-mm) coronary CT angiography
Number of subjects: 184
Study 24520943 — intervention group
Group type: COMPARATOR
Intervention: Standard spatial resolution (SR, 0.625-mm) coronary CT angiography
Number of subjects: 184
Study 22585166 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 4560
Study 22585166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4560
Study 20921465 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab-FOLFOX4
Number of subjects: 1183
Study 20921465 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX4
Number of subjects: 1183
Study 18294337 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ) + Sulfadoxine/Pyrimethamine (SDx/PYR) combination
Number of subjects: 86
Study 18294337 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose of CQ + SDx/PYR
Number of subjects: 86